FDA approves Spravato as a standalone (monotherapy) treatment for treatment-resistant depression
The FDA approved esketamine nasal spray for use without a concurrent oral antidepressant in adults with treatment-resistant depression. REMS certification and in-clinic monitoring requirements continue to apply.
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
Record details
- Agency
- FDA
- Jurisdiction
- United States (federal)
- Status
- Final action
- Published
- January 21, 2025
- Effective
- January 21, 2025
- Expires
- Not applicable / not verified
- Last checked
- August 24, 2026
Why it matters
Patients who cannot tolerate oral antidepressants gained a labeled pathway. Monitoring, certification, and setting requirements did not change.
Primary source
FDA — Spravato approval history and labeling (Drugs@FDA)
Back to the Regulatory Tracker.
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.